Drugplain

DERMOSCRIBE SEBORRHEIC DERMATITIS 1 g/100g

SULFUR, SALICYLIC ACID, HYDROCORTISONE · CREAM · DERMOSCRIBE PTY LTD

No Recall History
Plain English

Dermoscribe Seborrheic Dermatitis is a topical cream containing sulfur, salicylic acid, and hydrocortisone used to treat seborrheic dermatitis, a common skin condition that causes itching, redness, and flaking. This over-the-counter medication combines a corticosteroid with keratolytic agents to help reduce inflammation and improve skin symptoms.

Key Facts

Brand Name
DERMOSCRIBE SEBORRHEIC DERMATITIS
Generic Name
SULFUR, SALICYLIC ACID, HYDROCORTISONE
NDC Code (Product)
69683-202
Manufacturer
DERMOSCRIBE PTY LTD
Strength
1 g/100g
Dosage Form
CREAM
Route
TOPICAL
Marketing Status
Application #
M032
Drug Class
Corticosteroid [EPC]
Marketing Start
03/23/2015

Recall History

No Recall History

Frequently Asked Questions

What is DERMOSCRIBE SEBORRHEIC DERMATITIS used for?

Dermoscribe Seborrheic Dermatitis is a topical cream containing sulfur, salicylic acid, and hydrocortisone used to treat seborrheic dermatitis, a common skin condition that causes itching, redness, and flaking. This over-the-counter medication combines a corticosteroid with keratolytic agents to help reduce inflammation and improve skin symptoms.

Is DERMOSCRIBE SEBORRHEIC DERMATITIS a controlled substance?

DERMOSCRIBE SEBORRHEIC DERMATITIS is not classified as a controlled substance by the DEA.

What is the generic name for DERMOSCRIBE SEBORRHEIC DERMATITIS?

The generic name for DERMOSCRIBE SEBORRHEIC DERMATITIS is SULFUR, SALICYLIC ACID, HYDROCORTISONE. There are no other listed brand versions of SULFUR, SALICYLIC ACID, HYDROCORTISONE.

What is the NDC code for DERMOSCRIBE SEBORRHEIC DERMATITIS 1 g/100g?

The NDC (National Drug Code) for DERMOSCRIBE SEBORRHEIC DERMATITIS 1 g/100g is 69683-202, listed by DERMOSCRIBE PTY LTD.

Product NDC

69683-202

Package NDC

69683-202-11

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)